Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Eton Pharmaceuticals Inc
ETON
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$49.94
0.64
1.29%
Últ. Act.: Oct 22, 3:30 PM
$49.36
0.06
0.12%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Eton Pharmaceuticals Financials
Eton Pharmaceuticals (ETON) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone
The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.
Avi Kapoor
PRO
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $145.000M vs $121.326M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $120.000M vs $113.804M Est
Benzinga Newsdesk
PRO
Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of $0.07 per share from
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
